NCT00306475View on ClinicalTrials.gov

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Divalproex Sodium Extended-Release Tablets

divalproex sodium extended-release (ER) 1000 mg

DRUG

placebo

placebo identical in appearance to active comparator

Trial Locations (1)

37212

Psychiatric Hospital at Vanderbilt, Nashville

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

collaborator

Abbott

INDUSTRY

lead

Northwestern University

OTHER